Nicox SA has signed a shareholder loan agreement with Vester Finance for up to €6 million over three years, providing additional financial flexibility without immediate drawdown obligations. The loan can be repaid in new shares or cash, with potential dilution capped at 16% if fully drawn. Nicox is currently well-financed beyond 2027, supported by expected milestone payments and sales from its glaucoma drug NCX 470. Key upcoming milestones include NDA submissions for NCX 470 in the U.S. and China in 2026 and a Phase 3 clinical program in Japan starting in 2025. This facility complements existing financing and supports Nicox's strategic growth plans.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
